Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

(2018) Timothy F Cloughesy et al.   NEURO-ONCOLOGY

Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival

(2018) Prativa Sahoo et al.   Stem Cells International

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern

(2017) Michael Burger et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

(2017) Kei Hiraoka et al.   NEURO-ONCOLOGY

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model

(2017) Leah A. Mitchell et al.   NEURO-ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

(2016) L. Erdem-Eraslan et al.   CANCER RESEARCH

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma

(2016) Jacob J. Mandel et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival

(2016) Ranjith Babu et al.   JOURNAL OF NEUROSURGERY

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

(2016) Timothy F. Cloughesy et al.   Science Translational Medicine

Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas

(2016) D. Cory Adamson et al.   OncoTargets and Therapy

Novel chemotherapeutics and other therapies for treating high-grade glioma

(2015) Jennifer H Kang et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis

(2014) Z.-W. Yao et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Update on Anti-angiogenic Treatment for Malignant Gliomas

(2014) John F. de Groot et al.   Current Oncology Reports

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression

(2012) Omar D Perez et al.   MOLECULAR THERAPY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Candida Urinary Tract Infections—Treatment

(2011) John F. Fisher et al.   CLINICAL INFECTIOUS DISEASES

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

(2011) D. Ostertag et al.   NEURO-ONCOLOGY

5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes

(2010) Barbara Pardini et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways

(2009) Shruthi Naik et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Glioblastoma multiforme: a review of where we have been and where we are going

(2009) Cory Adamson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY